Literature DB >> 12889221

Assessment of disease activity.

G Valentini1, A J Silman, D Veale.   

Abstract

The objective of this study was to select a simple, feasible and validated core set of variables for the assessment of disease activity in systemic sclerosis. The subcommittee members extensively reviewed the studies in which the disease activity had been assessed, and analysed the construct validity and the feasibility of the criteria used in each study. The subcommittee members agreed on the possible use of either the European Scleroderma Study Group (ESSG) criteria for disease activity in SSc or the evaluation of selected cytokines and cell activation markers, found to be associated with distinct organ system involvement in recent studies. Despite the potential usefulness of cytokines and activation markers, most participants in the plenary session retained that their evaluation is not feasible in a number of centres, and their construct validity has not yet been assessed. The ESSG criteria for disease activity can be used for the time being to assess disease activity in clinical investigation studies as well as in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12889221

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  22 in total

1.  Peripheral T lymphocytes from patients with early systemic sclerosis co-cultured with autologous fibroblasts undergo an oligoclonal expansion similar to that occurring in the skin.

Authors:  Raffaele De Palma; Francesco Del Galdo; Salvatore Lupoli; Paolo Altucci; Gianfranco Abbate; Gabriele Valentini
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

2.  What does the clinician need to improve patient care in systemic sclerosis?

Authors:  Madelon C Vonk; Frank H J van den Hoogen; Piet L C M van Riel; Gabriele Valentini
Journal:  Ann Rheum Dis       Date:  2007-09       Impact factor: 19.103

3.  Human cytomegalovirus pp65 lower matrix protein: a humoral immunogen for systemic lupus erythematosus patients and autoantibody accelerator for NZB/W F1 mice.

Authors:  M Chang; M-R Pan; D-Y Chen; J-L Lan
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

4.  Seizures in systemic sclerosis.

Authors:  Fernando Glasner Araújo; Tiago Nardi Amaral; Simone Appenzeller; Jozélio Freire de Carvalho
Journal:  Rheumatol Int       Date:  2012-12-29       Impact factor: 2.631

5.  Circulating angiopoietin and Tie-2 levels in systemic sclerosis.

Authors:  James V Dunne; Kevin J Keen; Stephan F Van Eeden
Journal:  Rheumatol Int       Date:  2012-03-30       Impact factor: 2.631

6.  B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial.

Authors:  Silvia Bosello; Maria De Santis; Gina Lama; Cristina Spanò; Cristiana Angelucci; Barbara Tolusso; Gigliola Sica; Gianfranco Ferraccioli
Journal:  Arthritis Res Ther       Date:  2010-03-25       Impact factor: 5.156

7.  The arthropathy of systemic sclerosis: a 12 month prospective clinical and imaging study.

Authors:  Giovanni La Montagna; Antonio Sodano; Vittorio Capurro; Domenico Malesci; Gabriele Valentini
Journal:  Skeletal Radiol       Date:  2004-09-17       Impact factor: 2.199

8.  Serum galectin-3 level in systemic sclerosis.

Authors:  Suleyman Serdar Koca; Fatma Akbas; Metin Ozgen; Servet Yolbas; Nevin Ilhan; Baris Gundogdu; Ahmet Isik
Journal:  Clin Rheumatol       Date:  2013-08-03       Impact factor: 2.980

9.  Regional diastolic function by tissue Doppler echocardiography in systemic sclerosis: correlation with clinical variables.

Authors:  Edoardo Rosato; Stefania Maione; Antonio Vitarelli; Anna Giunta; Luca Fontanella; Laura Tanturri de Horatio; Francesco Cacciatore; Michele Proietti; Simonetta Pisarri; Felice Salsano
Journal:  Rheumatol Int       Date:  2008-12-28       Impact factor: 2.631

10.  Bone mineral density, bone turnover markers and fractures in patients with systemic sclerosis: a case control study.

Authors:  Marco Atteritano; Stefania Sorbara; Gianluca Bagnato; Giovanni Miceli; Donatella Sangari; Salvatore Morgante; Elisa Visalli; Gianfilippo Bagnato
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.